https://doi.org/10.33472/AFJBS.6.6.2024.7560-7572

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Characterization of Arginine and Glucose Effects on The Perfused Rat Pancreas' Glucagon and Insulin Release

Vanitha Naik[1*], Suba. K[2], Rakesh Verma[3], Shaikh Neeofar Rasheed[4], Madhusudan Sudhakarrao Bele[5], Shaikh Sana Jeelani[6], Bishwanath Mishra[7], Meesala Sudhakar[8], Yogesh Matta[9], Smita P Wasnik[10]

[1*]Assistant professor, BGS Medical College and Hospital, Nagaruru, Bangalore North
[2]Assistant Professor, Sri Sairam Engineering College, Sai Leo Nagar, West Tambaram, Chennai – 600 044. Tamil Nadu. India.
[3]Assistant Professor, Department of Pharmacology, Institute of Medical Science, BHU, Varanasi, Pin: 221005, India
[4]Assistant Professor Shri Sai College of Pharmacy, Khandala
[5]Assistant Professor Department of Zoology, Shri Vasantrao Naik Mahavidyalaya Dharni Dist, Amravati 444702
[6]Assistant professor, Aurangabad Pharmacy College, mitmita Aurangabad Pin: 431001
[7]Assistant Professor, Department of Pharmacology, Institute of Pharmacy & Technology, Salipur, Cuttack, Odisha- 754202, India
[8]Guest Lecturer, Department of Microbiology&Bioinformatics Department, Atal Bihari Vajpayee Viswavidyalayan, Bilaspur, Chhattisgarh, India
[9]Associate Professor, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur, India
[10]Associate Professor, Faculty of Pharmacology, Valmik Naik College of Pharmacy at Telwadi, Tal. Kannad Dist Aurangabad. Maharashtra 431003

Corresponding author: [1*]Dr Vanitha naik
[1*]Assistant professor BGS Medical College and Hospital Nagaruru, Banglore North
Email: [1*]Vanithasanjeev@gmail.com

Article Info

Volume 6, Issue 6, July 2024

Received: 03 June 2024

Accepted: 31 June 2024

Published: 25 July 2024

doi: 10.33472/AFJBS.6.6.2024.7560-7572

ABSTRACT:

The study investigates the impact of glucose and arginine on insulin and glucagon release in the perfused rat pancreas. Further research is required to fully comprehend how these amino acids and energy sources collectively influence pancreatic hormone secretion. We examined their effects on alpha and beta cell activity in the perfused rat pancreas, both individually and in combinations, to elucidate their mechanisms. Glucagon release is notably responsive to both glucose and arginine, underscoring distinct secretion patterns between pancreatic alpha and beta cells in response to these compounds. Varying arginine concentrations alongside 5.5 mM glucose revealed a biphasic response in insulin and glucagon release, with arginine enhancing insulin release and attenuating glucagon release compared to conditions without glucose. These findings suggest that glucose weakly inhibits arginine-induced glucagon release, influencing pancreatic alpha and beta cell dynamics through multiple pathways.

Keywords: Characterization, Arginine, Glucose, Perfused Rat Pancreas, Glucagon, Insulin Release

© 2024 Vanitha Naik, This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Creative Commons license, and indicate if changes were made

1. Introduction

The pancreas, a vital organ in blood glucose guideline, assumes a basic part by discharging the chemicals glucagon and insulin, which keep up with glucose homeostasis. By connecting with cellular glucose take-up, insulin, which is created by the β-cells of the islets of Langerhans, brings down blood glucose levels. Notwithstanding, by advancing glycogenolysis and gluconeogenesis in the liver, glucagon — which is released by α-cells of related islets — raises blood glucose levels. The pathophysiology of diabetes and other metabolic issues should be perceived to give light on the elements that influence the release of these atoms. Amino acids, for example, arginine and straightforward carbohydrates, for example, glucose have been distinguished as strong modulators of pancreatic compound release among these factors.
Insulotropic in nature, arginine is a semi-key amino corrosive destructive. It animates the release of insulin by utilizing it and in this manner affecting the intracellular flagging pathways saw as in pancreatic β-cells. Moreover, arginine has been displayed to influence glucagon discharge, but through somewhat figured out instruments. With exact control of the extracellular milieu and direct evaluation of compound release, the perfused rat pancreas model gives a significant exploratory stage to zeroing in on these frameworks in a controlled climate. A critical modulator of insulin release, glucose applies its properties through a few channels, for example, the conclusion of ATP-touchy potassium channels and the ensuing calcium flood in β-cells. The impacts of glucose on glucagon release are perplexing and require continuous

examination. Glucagon emission is ordinarily invigorated by low glucose levels and covered by high glucose concentrations. Notwithstanding, the collaboration among glucose and different parts, including arginine, in controlling the release of glucagon and insulin, keeps on being a subject of continuous exploration.

The impacts of arginine and glucose on the release of insulin and glucagon from the perfused rat pancreas are what we mean to illustrate. These headways permit us to capably screen compound emanation and intently copy physiological circumstances utilizing a perfusion system. With this strategy, the part response linkages and brief components of substance release are analyzed thing by thing, giving goodies of data about the fundamental pancreatic endocrine function of the administrative framework. Through our examination, we plan to add to a more profound comprehension of the physiological guideline of insulin and glucagon, with expected ramifications for the improvement of restorative treatments for diabetes leaders.

Background on Pancreatic Function

A fundamental organ, the pancreas plays two parts in the endocrine and stomach-related frameworks that are fundamental for keeping up with metabolic balance. One of its exocrine functions is the release of stomach-related substances into the small digestive tract, which supports the assimilation of enhancements. The islets of Langerhans, which have explicit cell types like beta cells that make insulin and alpha cells that release glucagon, do the endocrine function. These two chemicals are key to controlling blood glucose levels: glucagon animates the transformation of glycogen to glucose in the liver, helping blood glucose levels, while insulin works with the take-up of glucose into cells and its stockpiling as glycogen, consequently bringing down blood glucose levels. Stable glucose levels are guaranteed by the collaboration among insulin and glucagon, which is fundamental for ordinary physical process. Changes in this equilibrium can prompt metabolic issues, for example, diabetes mellitus, which is portrayed by constantly high glucose and related disarray. Deciding the administrative systems of pancreatic compound result, as well as the impacts of different energizers like glucose and amino acids (e.g., arginine), is fundamental for propelling restorative methodologies for diabetes and other metabolic problems.

Importance of Glucagon and Insulin

Important hormones called insulin and glucagon cooperate to control blood sugar levels, ensuring metabolic stability that is essential for overall health. A significant role in the digestion of glucose is played by insulin, which is basically released by pancreatic beta cells in response to elevated blood glucose levels following meals. It functions by facilitating the body's cells, including those in the liver, muscles, and fat, to absorb glucose. Here, it can either be quickly converted to energy or stored as glycogen. This cycle aids in lowering blood sugar levels and preventing hyperglycemia, which can lead to long-term problems like kidney failure, cardiovascular disease, and nerve damage.

Conversely, in response to low blood glucose, pancreatic alpha cells orchestrate and release glucagon, which acts to elevate blood glucose levels by promoting the breakdown of glycogen (glycogenolysis) in the liver and stimulating the synthesis of glucose from amino acids (gluconeogenesis). This counterregulatory hormone ensures a steady supply of glucose to power the brain and other tissues that depend on glucose as a necessary energy source. It is especially important during fasting periods or in between meals when blood sugar levels fall. The body maintains glucose homeostasis by modifying the actions of insulin and glucagon in response to changing nutritional conditions and metabolic demands throughout the day.

Insulin, glucagon, and previous glucose guidelines have broader metabolic effects. Insulin promotes lipid mixture and potential, inhibits lipolysis (fat breakdown), and influences the absorption of amino acids into cells, which affects protein digestion. Interestingly, glucagon

promotes the production of ketone bodies and lipolysis, allowing fats to be used as a choice energy source during fasting or postponed exercise.
The pathogenesis of diabetes mellitus, a chronic illness characterized by impaired insulin activity (type 2 diabetes) or absent insulin production (type 1 diabetes), is based on the dysregulation of insulin and glucagon release. Insulin deficiency is caused by immune system destruction of beta cells in type 1 diabetes, whereas impaired beta cell activity and insulin resistance contribute to elevated blood glucose levels in type 2 diabetes. The goal of restorative approaches that concentrate on the insulin and glucagon flagging pathways is to restore glucose homeostasis and prevent complications associated with diabetes. These approaches include pharmaceutical treatments and lifestyle mediations such food and exercise. Therefore, designing effective medications and improving outcomes for patients with diabetes and other metabolic disorders requires a thorough understanding of the roles that glucagon and insulin play in digestion.

2. Methods

Animals

Old-Evans male For every experiment, rats that were at least 30 weeks old and weighed 250 g were starved the night before. system for perfusion. There has just been disseminated a detailed account of the method for dissecting the rat pancreas and its blood supply. To put it briefly, sodium pentobarbital was administered to the rats in order to induce obviousness. After removing the pancreas, the stomach, the spleen, and a small portion of the duodenum, a nonrecirculating medium containing 1% egg whites, 3% dextran Krebs bicarbonate pad, and pH 7.4 was provided by perfusion. Every section's vein profluent was collected at regular intervals, and the perfusate was introduced into the celiac channel. Constant stream rates of 10 ml/min were maintained.

Design for experimentation

After a 15–20-minute equilibration interval and 20 minutes of maintaining perfusion, each specialist was given a side-arm needle at 0 minutes to try various things with either arginine or glucose alone. In various analyses, arginine was added to a perfusate that had already included glucose at 0 minutes. The combined effects of 19.2 mM arginine and glucose were the subject of those tests, which only showed the two specialists for a total of 0 minutes. Each pancreas was given a single concentration of glucose and arginine; subsequent feelings were not utilized in this investigation.

Measurements of insulin and glucagon

To guarantee the presence of insulin and glucagon, the perfusate was collected in tubes that had been cooled and mixed with 15% EDTA. Subsequently, it was frozen. The Unger and Eisentraut immunoassay was adjusted to measure glucagon using the exceptionally transparent Unger 30K antiserum. Half a milliliter of a glycine buffer with a pH of 8.8 and 0.25 percent human serum egg whites was mixed with two 0.2 milliliter portions of perfusate. It was then mixed with 0.4 ml of antiglucagon antiserum (last weakening 1:40,000). We used dextran-coated charcoal to separate bound and free glucagon after a 72-hour incubation period, and we counted the free fraction. The detection limit for this test is 20 pg/ml. There is a 15% bury measure coefficient and a 10% intra-examine variety coefficient. Insulin estimation for Grodsky and Forsham involved a radical shift in methodology.

Calculations

Whole insulin and glucagon released from areas beneath the bends during exploration still up in the air. The Km's (specialist concentrations producing half maximal sensation) and Ki's (specialist concentrations producing half-maximal sensation) obtained from the analysis of part reaction bends using the least squares technique are not fixed.

3. Results

Figures 1 and 2 illustrate the responses of insulin and glucagon to varying glucose concentrations. Figure 1 shows a moderate, non-phasic decrease in IRG release and a biphasic insulin release pattern in response to glucose mixtures. Figure 2 demonstrates the overall IRG and IRI release over 20 minutes of individual perfusion with glucose solutions ranging from 4.1 to 27.5 mM. Without glucose, the baseline IRG release was measured at 1.15 ± 0.11 ng/min, indicating insulin release was undetectable. Glucagon release decreased by approximately 20% at the lowest tested glucose concentration of 4.1 mM compared to fasting plasma glucose levels (75 mg/100 ml). At 16.7 mM glucose (300 mg/100 ml), IRG release was reduced by over 95%. The glucose concentration between 5 and 6 mM showed half-maximal inhibition of IRG release, with insulin release becoming detectable at 5.5 mM glucose (100 mg/100 ml). Half-maximal insulin release occurred at 9.7 and 10 mM glucose (160–180 mg/100 ml), reaching maximal IRI release at 16.7 mM glucose (300 mg/100 ml). These findings suggest that physiological glucose concentrations inhibit IRG release while stimulating IRI release. Pancreatic alpha cells appear more sensitive to glucose effects compared to beta cells, as indicated by both clearance and Km values.



Figure 1: Results show that glucose affects the release of glucagon and insulin from the pancreas of rats perfused in vitro, with a mean ± standard error (n=6).

Figure 2: The in vitro perfused rat pancreas' insulin and glucagon output was compared to that of various glucose concentrations.

Figures 3 and 4 show the insulin and glucagon responses to arginine. Arginine triggered biphasic IRG emission in the absence of glucose, even at doses that resulted in peak discharge (Fig. 3), although IRI reactions remained monophasic. On the other hand, it was common for IRG and IRI reactions to diminish as one got closer to the furthest cutoff of the arginine implantations. For arginine blends ranging from 2.1 to 38.4 mM, the direct IRG and IRI responses are displayed in Figure 4 for a duration of 20 minutes. (Remember that Figure 4's scale is slightly different from Figure 2's scale.) At concentrations that produced almost minimal IRI release, arginine activated measurable IRG release. The optimal concentration for both IRG release times was around 13 mM arginine. The half-life (Km) was 3–4 mM for both of the arginine-induced glucagon release times. When injecting arginine at doses below 6 mM, insulin release was negligible. At arginine concentrations of 19–20 mM, peak IRI responses were observed, with a Km of approximately 13 mM for arginine-stimulated IRI release. Despite variations in arginine concentrations, the maximum responses for IRG and IRI were nearly equal quantitatively (900 ng/20 min). Arginine induced biphasic responses in glucagon release while insulin release showed a monophasic pattern, highlighting distinct secretion patterns between pancreatic beta and alpha cells in response to arginine. The impact of arginine on glucagon release was less pronounced compared to its effect on insulin release, mirroring findings seen with glucose.



Figure 3: Arginine's impacts on the mean ±SE of insulin and glucagon released from a rat pancreas perfused in vitro.



Figure 4: Contrasting the impacts of various arginine concentrations on the in vitro perfused rat pancreas' development of insulin and glucagon.

The study aimed to investigate how glucose and arginine influence the secretion of insulin (IRI) and glucagon (IRG). Specifically, the research explored how varying concentrations of one chemical affected the secretion patterns of the other, providing insights into their combined effects on IRG and IRI release.



Figure 5: Measurement of insulin and glucagon secretion by the in vitro perfused rat pancreas in response to 5.5 mM glucose, as a function of different arginine concentrations, with mean ± SE.

Insulin and glucagon responses triggered by arginine in the presence of 5.5 mM glucose are illustrated in Figures 5 and 6. Figure 5 shows that arginine induced a biphasic release of IRG and IRI when combined with 5.5 mM glucose. In contrast, Figure 3 demonstrates that varying concentrations of arginine alone did not result in biphasic IRI release, underscoring the significant influence of glucose on IRI responses. Figure 6 depicts an increase in IRI release and a decrease in IRG release with increasing concentrations of arginine alone. Glucose did not alter the Km for IRG release (3-4 mM), while arginine reduced the Km for IRI release from 12-14 mM to 5-6 mM. Consequently, the thresholds for IRG responses to arginine remained

unaffected by glucose's inhibitory effects. However, glucose did modify the sensitivity and secretion profile of IRI responses to arginine.



Figure 6: Insulin and glucagon reactions to arginine both without any glucose (0) and at 5.5 mM glucose.

At 3.2- or 19.2-mM arginine, glucose triggers the release of glucagon and insulin, respectively (Figs. 7-9). The combined glucose-arginine mix elicited biphasic responses from the IRG and IRI at glucose concentrations greater than 4.1 mM (Fig. 7). In contrast to IRI release, IRG reactions decreased as glucose concentrations increased, but IRI responses increased.



Figure 7: effect of various glucose concentrations on insulin and glucagon reactions to 3.2 mM arginine, mean ± SE.

The scope of 10-27.5 mM glucose was the most extreme hindrance of IRG release (> around 100 percent) seen at 3.2 mM arginine (Fig. 8). The Ki was like that saw with glucose alone, at 5-6 mM. Along these lines, despite the fact that arginine seemed to release more IRG than it, the inhibitory impact of glucose gave off an impression of being the equivalent paying little mind to arginine accessibility.



Figure 8: Reactions between arginine and insulin(0) and glucagon (-), as a function of glucose. With different glucose concentrations in view, each point addresses the mean ±-SE of the total chemical produced after individual 20-minute arginine implantations.

As glucose concentrations increased, IRI responses to arginine also increased, reaching their peak at 27.5 mM glucose, the highest concentration tested. Conversely, at glucose levels below 4.1 mM (75 mg/100 ml), the availability of 3.2 mM arginine limited IRI responses. Under these conditions, perfusate IRI levels rose before reaching optimal arginine combination levels. Therefore, it was prudent to gather comprehensive IRI response data using a consistent combination of arginine and glucose. The experiments involved simultaneous introduction of 19.2 mM arginine with varying glucose concentrations up to 27.5 mM. Figure 9 illustrates that simultaneous stimulation of glucose and arginine led to enhanced IRI responses compared to individual stimulations. Ultimately, the Km and the glucose concentration that elicited maximal release were similar in both scenarios, approximately 9-10 mM for glucose and 15-17 mM for arginine, respectively.



Figure 9: Insulin reactions to glucose both all alone (0) and within the sight of 19.2 mM arginine.

Along these lines, expanding arginine expanded IRI responses above what might be generally anticipated from glucose alone, yet it affected beta cells' abhorrence for glucose. Like this, expanding arginine during the glucose combination prompted an expansion in IRG release without changing the revultion of alpha cells to glucose. Utilizing the exemplary Lineweaver-Burk twofold correlative curves to inspect segment response information got close to maximal speed for IRI and IRG release created reliable outcomes with a non-serious correspondence of glucose and arginine on both pancreatic alpha and beta cell function.

4. Discussion

Ongoing research seeks further insights into how glucose and arginine affect beta and alpha cell activity in the pancreas. Using a perfused rat pancreatic model, it became feasible to independently and simultaneously study the effects of each compound on comprehensive hormone responses. Current investigations with the perfused rat pancreas suggest that the relationship between insulin and glucose responses mirrors findings from previous studies on insulin release dynamics. However, the definitive determination of the Km for glucose-stimulated insulin release has not been universally established across studies by Coore and Randle using rabbit pancreatic components, Malaisse, Malaisse-Lagae, and Wright using rat pancreatic components, and Montague and Taylor using isolated rat islets.

The effects of glucose on glucagon secretion align with observations in humans and dogs, and in vitro experiments using the perfused pancreas technique indicate a high sensitivity of pancreatic alpha cells to glucose. According to current research findings, glucose appears to regulate alpha cells more effectively than beta cells at or near physiological levels. The Km for glucose-induced insulin release (9-10 mM) exceeds that for glucose-induced inhibition of glucagon production (5-6 mM or 90-110 mg/100 ml). These observations contrast with earlier findings suggesting alpha cells exhibit minimal responsiveness to glucose in studies with isolated pancreatic cells and islets, where glucose concentrations as high as 16.7 mM (300 mg/100 ml) often result in negligible suppression of glucagon secretion. These discrepancies may stem from pancreatic tissue damage during isolation or residual acinar tissue fragments, which may not adequately replicate physiological glucagon secretion concentrations in vitro.

Recent studies affirm that arginine can induce insulin release independently of glucose. Differences in experimental methodologies and sub-stimulatory arginine concentrations may explain why previous researchers failed to detect this effect, as these methods may not be as sensitive to low levels of insulin release as the perfused pancreas model. However, glucose and arginine demonstrate structural similarities in their ability to stimulate insulin release. Both compounds exhibit significant insulin response magnitudes and lower Km values for glucose-stimulated insulin release (9-10 mM) compared to arginine (12-14 mM), highlighting their similar mechanisms of action. Arginine primarily enhances glucagon secretion rather than influencing beta cell function.

Arginine stimulates glucagon release at concentrations below 1 mM, with half-maximal responses occurring at 3-4 mM arginine. The observed hormone response pattern with an amino acid mixture mimicking normal rat serum aligns with the response pattern observed with arginine alone, suggesting that arginine's effect on glucagon release may reflect general pancreatic alpha cell responsiveness to amino acids.

Translating laboratory findings to real-world scenarios requires careful consideration. Recent research indicates that post-absorptive physiological glucose levels and major amino acids (< 2 and < 5.5 mM, respectively) minimally stimulate insulin release while influencing glucagon release. This suggests that these concentrations may not regulate basal insulin release during the post-absorptive period in rats or possibly humans. These glucose and amino acid

concentrations may exert a more significant influence on basal glucagon release regulation based on our experimental findings.

A pertinent question under investigation is whether glucose and arginine exert their effects through a common pathway. According to current evidence, they do not. While insulin responses to glucose typically exhibit a biphasic pattern, arginine-induced insulin release remains monophasic even at maximal stimulatory doses. Furthermore, the maximal insulin release induced by glucose or arginine differs significantly compared to their individual effects. This divergence occurs without significant changes in Km values for either arginine or glucose and suggests they may interact with different receptor sites on beta cells, as indicated by traditional Lineweaver-Burk analysis. Although both glucose and arginine may influence insulin secretion through multiple mechanisms, their lack of competition suggests they do not act at the same receptor sites on beta cells.

Research on glucagon responses indicates that glucose and arginine affect alpha cells differently. Arginine prominently stimulates glucagon release, whereas glucose inhibits it. The Km for glucose-induced glucagon inhibition and arginine-induced glucagon stimulation appear to reflect distinct combinations of these compounds. Glucose seems to weakly inhibit arginine-induced glucagon release, consistent with classic Lineweaver-Burk experiments. Studies on insulin and glucagon secretion suggest that arginine and glucose act through distinct pathways. These findings lend support to the concept that beta and alpha cells possess distinct receptors for these compounds. Constant studies demonstrating that mammalian islets do not fundamentally metabolize arginine and that a non-metabolizable form of arginine can enhance insulin and glucagon secretion make the existence of an arginine receptor an intriguing concept. Additionally, this study aimed to determine whether glucose and arginine exert similar effects on pancreatic beta and alpha cells. Specifically, does arginine stimulate insulin and glucagon release while glucose similarly enhances insulin release and inhibits glucagon release? Given the inherent differences in alpha and beta cell characteristics, further clarification is necessary. Glucose induces rapid, non-phasic glucagon release inhibition and biphasic insulin release initiation, a secretion pattern distinct from insulin release and glucagon inhibition patterns. The Km for arginine-induced insulin release varies from 12-14 mM, while the Km for arginine-induced glucagon release inhibition varies from 2-4 mM. Similarly, the Km for glucose-induced glucagon inhibition (5-6 mM) is lower than that for glucose-induced insulin release (9-10 mM). These distinct secretion patterns and cell-specific responses to arginine and glucose suggest that these compounds interact with different aspects of each cell.

Theoretically, glucagon may directly stimulate insulin secretion, while insulin may directly inhibit glucagon secretion under physiological conditions. Some findings from the current study challenge the notion that these primary actions may be modulated by endogenous factors. Specifically, there was no evidence of biphasic glucagon inhibition at glucose concentrations that induce biphasic insulin secretion. Additionally, increasing arginine concentrations in the presence of a constant glucose level (5.5 mM) minimally increased insulin and glucagon production without significant changes in alpha cell arginine sensitivity. These findings suggest that insulin may independently affect glucagon secretion, regardless of its glucose-mediated effects. In vivo observations support similar conclusions: administering pharmacological doses of exogenous insulin or glucose mixture, which elevate endogenous plasma insulin levels, does not fully inhibit glucagon response and subsequent plasma glucose decrease. Studies investigating insulin's suppressive effects on glucagon secretion have often been conducted in vivo, where insulin's effects extend beyond direct alpha cell effects. Glucagon pharmacological components activate IRI secretion in both living organisms and laboratory settings. However, even at that glucose concentration (50 mg/100 ml), insulin release was not induced in the present study, despite the fact that modest amounts of arginine, which are typically found in human peripheral venous blood, were detected. Therefore, it seems unlikely that glucagon

directly stimulates insulin release at physiological levels unless released glucagon bypasses the pancreatic beta cell.

5. Conclusion

Studying how glucose and arginine affect insulin and glucagon secretion in perfused rat pancreas reveals unexpected regulatory mechanisms crucial to understanding glucose homeostasis. This examination showed that while glucose supernaturally enlivens the release of insulin, arginine essentially helps the release of glucagon. Thinking about everything, the ongoing survey quantitatively illustrates the reactions of the pancreatic beta and alpha cells to arginine and glucose. Contrasted with insulin release, glucagon release is more delicate with the impacts of both arginine and glucose. Despite the fact that arginine and glucose seem, by all accounts, to be connected, they distinctively affect the release of glucagon and insulin. Arginine animates insulin release in a clear way, but it does as such in an unexpected way in comparison to glucose. A unimportant inhibitor of arginine-invigorated glucagon release is glucose. At the sums generated in these tests, endogenous glucagon and insulin appear to impact each other's emanation essentially.

6. REFERENCES

1. Abu-Basha, E. A., Yibchok-Anun, S., & Hsu, W. H. (2002). Glucose dependency of arginine vasopressin [ndash] induced insulin and glucagon release from the perfused rat pancreas. Metabolism-Clinical and Experimental, 51(9), 1184-1190. https://www.metabolismjournal.com/article/S0026-0495(02)00063-X/abstract
2. Brandhorst H, Brendel MD, Eckhard M, Bretzel RG, Brandhorst D 2005 Influence of neutral protease activity on human islet isolation outcome. Transplant Proc 37:241–242 https://journals.lww.com/transplantjournal/fulltext/2004/07271/Influence_of_Neutral_Protease_Activity_on_Human.468.aspx
3. Brunicardi FC, Atiya A, Moldovan S, Lee TC, Fagan SP, Kleinman RM, Adrian TE, Coy DH, Walsh JH, Fisher WE 2003 Activation of somatostatin receptor subtype 2 inhibits insulin secretion in the isolated perfused human pancreas. Pancreas 27: e84 –e89 https://journals.lww.com/pancreasjournal/fulltext/2003/11000/Activation_of_Somatostatin_Receptor_Subtype_2.19.aspx
4. Cejvan K, Coy DH, Efendic S 2003 Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats. Diabetes 52:1176 –1181 https://diabetesjournals.org/diabetes/article-abstract/52/5/1176/13932
5. Egido, E. M., Hernández, R., Marco, J., & Silvestre, R. A. (2009). Effect of obestatin on insulin, glucagon and somatostatin secretion in the perfused rat pancreas. Regulatory peptides, 152(1-3), 61-66. https://www.sciencedirect.com/science/article/pii/S0167011508001390
6. Farilla L, Bulotta A, Hirshberg B, Li CS, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R 2003 Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144:5149 –5158 https://academic.oup.com/endo/article-abstract/144/12/5149/2880380
7. Guenifi, A., Ahrén, B., & Abdel-Halim, S. M. (2001). Differential effects of glucagon-like peptide-1 (7-36) amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro. Pancreas, 22(1), 58-64. https://journals.lww.com/pancreasjournal/fulltext/2001/01000/Differential_Effects_of_Glucagon_like_Peptide_1.10.aspx

8. Ludvigsen E, Olsson R, Stridsberg M, Janson ET, Sandler S 2004 Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats. J Histochem Cytochem 52:391– 400 https://journals.sagepub.com/doi/abs/10.1177/002215540405200310
9. Maruszczak, K., Rasmussen, C., Ceutz, F. R., Ørgaard, A., Elmelund, E., Richter, M. M., ... & Wewer Albrechtsen, N. J. (2022). Arginine-induced glucagon secretion and glucagon-induced enhancement of amino acid catabolism are not influenced by ambient glucose levels in mice. American Journal of Physiology-Endocrinology and Metabolism, 323(3), E207-E214. https://journals.physiology.org/doi/abs/10.1152/ajpendo.00122.2022
10. Rosati, B., Marchetti, P., Crociani, O., Lecchi, M., Lupi, R., Arcangeli, A., ... & Wanke, E. (2000). Glucose- and arginine- induced insulin secretion by human pancreatic β-cells: the role of HERG K+ channels in firing and release. The FASEB Journal, 14(15), 2601-2610. https://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fj.00-0077com
11. Silvestre, R. A., Rodrıguez-Gallardo, J., Jodka, C., Parkes, D. G., Pittner, R. A., Young, A. A., & Marco, J. (2001). Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. American Journal of Physiology-Endocrinology and Metabolism, 280(3), E443-E449. https://journals.physiology.org/doi/abs/10.1152/ajpendo.2001.280.3.E443
12. Strowski MZ, Kohler M, Chen HY, Trumbauer ME, Li Z, Szalkowski D, Gopal-Truter S, Fisher JK, Schaeffer JM, Blake AD, Zhang BB, Wilkinson HA 2003 Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Mol Endocrinol 17:93–106 https://academic.oup.com/mend/article-abstract/17/1/93/2741803
13. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B 2002 Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the -cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51:1443–1452 https://diabetesjournals.org/diabetes/article-abstract/51/5/1443/34567
14. Wang XP, Norman MA, Yang J, Cheung A, Moldovan S, Demayo FJ, Brunicardi FC 2004 Double-gene ablation of SSTR1 and SSTR5 results in hyperinsulinemia and improved glucose tolerance in mice. Surgery 136:585–592 https://www.sciencedirect.com/science/article/pii/S0039606004003010
15. Yibchok-anun, S., Abu-Basha, E. A., Yao, C. Y., Panichkriangkrai, W., & Hsu, W. H. (2004). The role of arginine vasopressin in diabetes-associated increase in glucagon secretion. Regulatory peptides, 122(3), 157-162. https://www.sciencedirect.com/science/article/pii/S0167011504002009